- AimedBio’s FGFR3-targeting ADC, AMB302, has been selected by the Korea Drug Development Fund (KDDF), securing two years of support for
non-clinical research.
- The program focuses on bladder
cancer and glioblastoma as lead indications.
- Preclinical studies have demonstrated strong efficacy and favorable safety, and the company plans to submit an IND application to the U.S. FDA in the first half of 2024.